Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Terminated 1Recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2Thoracic 1Sarcoma 1Other solid neoplasm 1Myeloid 1Lymphoid 1Head & Neck 1Gynecologic 1Genitourinary 1CNS 1

Conditions

Colorectal Neoplasms 25Ovarian Neoplasms 19Neoplasms 12Fallopian Tube Neoplasms 12Carcinoma, Hepatocellular 11Endometrial Neoplasms 7Neoplasm Metastasis 6Colonic Neoplasms 6Carcinoma, Non-Small-Cell Lung 6Glioblastoma 4Brain Neoplasms 4Squamous Cell Carcinoma of Head and Neck 3Rectal Neoplasms 3Lung Neoplasms 3Liver Neoplasms 3Digestive System Neoplasms 3Uterine Cervical Neoplasms 2Sarcoma 2Recurrence 2Parkinson Disease 4, Autosomal Dominant Lewy Body 2Mouth Neoplasms 2Lymphoid Interstitial Pneumonia 2Intestinal Neoplasms 2Gastrointestinal Neoplasms 2Carcinoma, Renal Cell 2Carcinoma, Ovarian Epithelial 2Brenner Tumor 2Breast Neoplasms 2Biliary Tract Neoplasms 2Astrocytoma 2

Interventions

Letrozole 25Fulvestrant 25Specimen Handling 19ribociclib 16Capecitabine 16pembrolizumab 14palbociclib 14Paclitaxel 14Trastuzumab 13Carboplatin 13exemestane 12abemaciclib 12Tamoxifen 12Anastrozole 12Magnetic Resonance Spectroscopy 11trastuzumab deruxtecan 8pertuzumab 8Biopsy 8Goserelin 7inavolisib 6giredestrant 6Cyclophosphamide 6130-nm albumin-bound paclitaxel 6patritumab deruxtecan 5eribulin 5elacestrant 5Taxes 5Standard of Care 5Radiotherapy 5Gonadotropin-Releasing Hormone 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Breast Neoplasms × Bevacizumab × 30 days × Clear all
NCT05579366 2026-06-03

RAINFOL-01

Genmab

Phase 1/2 Recruiting
884 enrolled
BreastGynecologicOther solid neoplasmThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Fallopian Tube Neoplasms, Mesothelioma, Ovarian Neoplasms, Uterine Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT01552434 2026-05-15

Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease

M.D. Anderson Cancer Center

Phase 1 Terminated
154 enrolled
BreastCNSGenitourinaryHead & NeckLymphoidMyeloidSarcoma

Breast Neoplasms, Carcinoma, Transitional Cell, Endocrine Gland Neoplasms, Castleman Disease, Mouth Neoplasms, Neoplasm Metastasis, Neoplasms, Pharyngeal Neoplasms, Recurrence, Sarcoma, Soft Tissue Neoplasms, Thyroid Neoplasms, Urologic Neoplasms, Neurofibromatosis 2, Lymphangioleiomyomatosis, Neoplasms, Mesothelial, Erdheim-Chester Disease

Data powered by HemOnc (CC BY 4.0) Colophon âš¡